

human Bombesin Receptor BB₂ Cell Line

Product No.: ES-582-C

Lot No.: M1W-C1

Material Provided

Cells:	2 x 1 mL frozen aliquot (ES-582-CV)
Format:	~2.5 x 10 ⁶ cells /mL in freezing medium

Product Information

Cellular Background:	CHO-K1
Cell Line Development:	Our proprietary bicistronic expression plasmid containing the sequence coding for the human Bombesin receptor BB ₂ was transfected in CHO-K1 cells. Geneticin-resistant clones were obtained by limit dilution and compared for receptor expression levels using a radioligand binding assay and a fluorescent calcium flux assay. A clone with a high receptor expression level and a good calcium flux assay response was selected.
DNA Sequence:	Identical to coding sequence of GenBank M73481.1.
Corresponding Protein Sequence:	Identical to GenBank NP_005305.1.
Receptor expression level (B _{max}):	Estimated to be 40 pmol/mg protein, using [¹²⁵ I]-GRP
K _d for the above radioligand:	0.1 nM
Shipping Conditions:	Shipped on dry ice. Please ensure dry ice is still present in the package upon receipt or contact customer support.
Storage Conditions:	Store in liquid nitrogen (vapor phase) immediately upon receipt.



Quality Control

The EC₅₀ for a reference agonist was determined in Calcium flux assay. A mycoplasma test was performed using MycoAlert® (Lonza) mycoplasma detection kit. We certify that these results meet our quality release criteria.

Gastrin-Releasing Peptide (human) (EC₅₀): 0.04 nM

Stability: Cells were kept in continuous culture for at least 60 days and showed no decrease of receptor expression level in a saturation binding assay (stable B_{max} and K_d) and no decrease in functional response (EC₅₀, E_{max} in calcium flux assay).

Mycoplasma: This cell line tested negative for mycoplasma.

Assay Procedures

We have shown for many of our GPCR cell lines that freshly thawed cells respond with the same pharmacology as cultured cells. All of our products validated in this way are available as frozen ready-to-use cells in our catalogue. This demonstrates that cells can be prepared and frozen in advance of a screening campaign simplifying assay logistics.



Recommended Cell Culture Conditions (CHO-K1)

- The recommended media catalogue number and supplier reference information are listed in this Product Technical Data Sheet (last page). Media composition is specifically defined for each cell type and receptor expression selection. The use of incorrect media or component substitutions can lead to reduced cell viability, growth issues and/or altered receptor expression.
- Cells undergo major stress upon thawing, and need to adapt to their new environment which may initially affect cell adherence and growth rates. The initial recovery of the cells, and initial doubling time, will vary from laboratory to laboratory, reflecting differences in the origin of culture media and serum, and differences in methodology used within each laboratory.
- For the initial period of cell growth (i.e. until cells have reached Log-phase, typically 4-10 days), we strongly recommend removal of the antibiotics (G418, Zeocin™, Puromycin, Blasticidin, Hygromycin, Penicillin and Streptomycin) from the culture media. Immediately after thawing, cells may be more permeable to antibiotics, and a higher intracellular antibiotic concentration may result as a consequence. Antibiotics should be re-introduced when cells have recovered from the thawing stress.

Growth Medium: Ham's F-12, 10% FBS, 0.4 mg/ml G418 (receptor expression selection).

Freezing Medium: Ham's F-12, 10% FBS with 10% DMSO, without selection agents.

Thawing Cells: Using appropriate personal protective equipment, rapidly place the frozen aliquot in a 37°C water bath (do not submerge) and agitate until its content is thawed completely. Immediately remove from water bath, spray aliquot with 70% ethanol and wipe excess. Under aseptic conditions using a sterile pipette, transfer content to a sterile centrifuge tube containing 10 mL growth medium without antibiotics, pre-warmed at 37°C, and centrifuge (150 x g, 5 min). Discard supernatant using a sterile pipette. Resuspend cell pellet in 10 mL of pre-warmed growth medium without antibiotics by pipetting up and down to break up any clumps, and transfer to an appropriate culture flask (e.g. T-25, T-75 or T-175, see recommended seeding density below). Cells are cultured as a monolayer at 37°C in a humidified atmosphere with 5% CO₂.

Recommended Seeding Density:	Thawing:	15,000 – 33,000 cells/cm ²
	Log-phase:	11,000 – 15,000 cells/cm ²

Troubleshooting: Initial doubling time can vary between 18 and 96 hours (Average = 25 hours). If cells are still not adhering after 48 hours or grow very slowly, we recommend maintaining the cells in culture and not replacing the media before 5-6 days (cells secrete factors that can help with adherence and growth). If confluence is still <50% after 5-6 days, it is recommended that you replace the media with fresh media (without antibiotics). Do not passage the cells until they reach 80-90% confluence (Log-phase). If cells have not recovered after 10-12 days, please contact our Technical Support.

Culture Protocol: Under aseptic conditions, cells are grown to 80% confluence (Log-phase) and trypsinized (0.05% trypsin/0.5 mM EDTA in calcium and magnesium-free PBS). See recommended seeding density for Log-phase above.

Banking Protocol: Cells are grown to 70-80% confluence (Log-phase). Under aseptic conditions, remove medium and rinse the flask with an appropriate volume of calcium and magnesium-free PBS (example 10 mL for T-175). Trypsinize (0.05% trypsin/0.5 mM EDTA in calcium and magnesium-free PBS) to detach cells (example 5 mL for T-175), let stand 5-10 min at 37°C. Add fresh, room temperature growth medium (without antibiotics) to stop trypsinization and dilute EDTA (example 10 mL for T-175). Transfer cells to a sterile centrifuge tube and centrifuge (150 x g, 5 min). Discard supernatant using a sterile pipette. Resuspend cell pellet in ice-cold freezing medium by pipetting up and down to break up any clumps. Count cells and rapidly aliquot at the selected cell density (e.g. 2.5 x 10⁶ cells/mL) in sterile polypropylene cryovials. Use appropriate material to ensure slow cooling (about -1°C/min) until -70°C. Transfer vials into a liquid nitrogen tank (vapor phase) for storage.

Typical Product Data - Calcium Assay (Fluorescence)




Figure 1. Agonist Response in Fluo-4 Calcium Flux assay

An agonist dose-response experiment was performed in 96-well format using 25,000 cells/well. Calcium Fluorescence was measured on FDSS 6000 instrument (Hamamatsu Photonics). Data from a representative experiment are shown.

Typical Product Data -Radioligand Binding Assay (Filtration)





Figure 2: Saturation Binding Assay Curve (Filtration)

A saturation binding assay was performed in 96-well format using 0.1 µg membranes/well. Counts per minute (cpm) were measured on a TopCount® instrument. Data from a representative experiment are shown.



Agonist / Antagonist	IC ₅₀ (M)
Gastrin-Releasing Peptide (human)	1.8 x 10 ⁻¹⁰
(D-Phe ⁶ , Leu-NHET ¹³ , des-Met ¹⁴)-Bombesin (6-14)	1.6 x 10 ⁻⁸
Neuromedin B	3.3 x 10 ⁻⁷

Figure 3: Competition Binding Assay Curve (Filtration)

A competition binding assay was performed in 96-well format using 0.1 µg membranes/well. Displacement of 0.042 nM [¹²⁵I]-Gastrin Releasing Peptide was used. Counts per minute (cpm) were measured on a TopCount® instrument. Data from a representative experiment are shown.



Calcium Assay Procedure (Fluorescence)

Dye solution: 5 μ M Fluo-4 AM (Molecular Probes, P-6867), 1 mg/mL Pluronic acid in Assay Buffer

Assay Buffer: 2.5 mM Probenicid, 0.1% BSA, 0.05% Gelatin, 135 mM NaCl, 5 mM KCl, 1.8 mM CaCl_2 , 1 mM MgCl_2 , 10 mM HEPES, 5.6 mM Glucose, pH 7.4

Controls: Maximal Signal: 0.4% Triton X-100 (0.2% final) in Assay Buffer

Minimum signal: 0.4% Triton X-100 (0.2% final), 20 mM EGTA (10 mM final) in Assay Buffer

Reader: FDSS 6000 (Hamamatsu Photonics), Excitation 480 nm / Emission 520 to 560 nm, 96-well

Day 1			
1. Cell Culture and Harvesting:	Grow cells (mid-log phase) in culture medium without antibiotics for 18 hours, Detach gently with PBS / 0.5 mM EDTA, pH 7.4, Recover by centrifugation, Resuspend in medium without antibiotics at 2.5×10^5 cells/mL.		
2. Cell Seeding	Distribute 100 μ L (i.e. 25,000 cells) in each well of a 96 well black, clear bottom TC sterile plate, incubate overnight in a cell culture incubator (37°C, 5% CO_2).		
Day 2			
3. Cell Loading	Remove the media, and add 100 μ L/well of Dye solution.		
4. Incubation	Incubate the assay plate for 1 hour at 37°C in a cell culture incubator.		
5. Ligands and compound plates preparation:	Prepare serial dilutions of 2x concentrated ligands in Assay Buffer, Dispense 100 μ L/well of diluted ligand in a 96-well plate. <i>Note: Assay can be miniaturized to 384-well format.</i>		
6. Dye Washing	Drain the media and wash the wells twice with 100 μ L/well Assay Buffer,		
7. Buffer/Antagonist addition	<table border="1" style="width: 100%;"> <tr> <td style="width: 50%;">Agonist assay: Add Assay Buffer to make a total of 50 μL</td> <td style="width: 50%;">Antagonist Assay: Add 2x antagonist dilution in Assay Buffer to make a total of 50 μL</td> </tr> </table>	Agonist assay: Add Assay Buffer to make a total of 50 μ L	Antagonist Assay: Add 2x antagonist dilution in Assay Buffer to make a total of 50 μ L
Agonist assay: Add Assay Buffer to make a total of 50 μ L	Antagonist Assay: Add 2x antagonist dilution in Assay Buffer to make a total of 50 μ L		
8. Equilibration	Incubate the plate for 20 min at room temperature in the dark.		
9. Plate Reading:	<table border="1" style="width: 100%;"> <tr> <td style="width: 50%;">Using the reader's injection system, inject 50 μL per well of 2x agonist solutions in Assay Buffer, and immediately record relative light emission for 90 seconds.</td> <td style="width: 50%;">Using the reader's injection system, inject 50 μL per well of 2x concentrated reference agonist in Assay Buffer (final EC_{80} concentration), and immediately record relative light emission for 90 seconds.</td> </tr> </table>	Using the reader's injection system, inject 50 μ L per well of 2x agonist solutions in Assay Buffer, and immediately record relative light emission for 90 seconds.	Using the reader's injection system, inject 50 μ L per well of 2x concentrated reference agonist in Assay Buffer (final EC_{80} concentration), and immediately record relative light emission for 90 seconds.
Using the reader's injection system, inject 50 μ L per well of 2x agonist solutions in Assay Buffer, and immediately record relative light emission for 90 seconds.	Using the reader's injection system, inject 50 μ L per well of 2x concentrated reference agonist in Assay Buffer (final EC_{80} concentration), and immediately record relative light emission for 90 seconds.		
10. Data Analysis:	The fluorescent signal is expressed as the ratio relative to the first measurement (i.e. before dispensing), and the maximal value of this ratio during the measurement interval is used to draw sigmoidal dose-response curves.		

Important Notes:

- Probenicid is prepared as a 250 mM solution in a 50:50 mixture of 1N NaOH : Assay Buffer.



Membrane Radioligand Binding Assay Procedure (Filtration)

Note: The following are recommended assay conditions and may differ from the conditions used to generate the typical data shown in the above section.

Assay Buffer:	50 mM Tris-HCl pH 7.4 at 27°C, 0.3% BSA
Wash Buffer:	50 mM Tris-HCl pH 7.4
Radioligand:	[¹²⁵ I]-Gastrin Releasing Peptide (Revvity # NEX421)
Filters:	Unifilter 96 GF/C (Revvity # 6055690)

Membrane Binding Protocol:

Binding assays were performed in 200 µL total volume according to the following conditions. All dilutions are performed in assay buffer:

1. Membrane dilution:	0.1 µg of membranes per well, diluted in order to dispense 150µL/well. Keep on ice.
2. Assembly on ice (in 96 Deep well plate) Saturation Binding:	<ul style="list-style-type: none">• 25 µL of assay buffer or of unlabeled ligand (GRP (human), 100 nM final) for determination of non specific binding• 25 µL of radioligand at increasing concentrations (see figure 2)• 150 µL of diluted membranes
Competition Binding:	<ul style="list-style-type: none">• 25 µL competitor ligand at increasing concentrations (see figure 3)• 25 µL of radioligand (0.0125 nM final)• 150 µL of diluted membranes
3. Incubation:	60 min at 27°C.
4. Filters preparation:	GF/C filters were presoaked in 0.5 % PEI at room temperature for at least 30 min.
5. Filtration:	Aspirate and wash 9 x 500 µL with ice cold wash buffer using a FilterMate Harvester.
6. Counting:	Add 30 µL/well of MicroScint™-O (Revvity # 6013611), cover filter with a TopSeal-A PLUS (Revvity # 6050185) and read on a TopCount®.

References

1. Giladi E, Nagalla SR, Spindel ER. (1993) Molecular cloning and characterization of receptors for the mammalian bombesin-like peptides. *J Mol Neurosci.* 4:41-54.
2. Benya RV, Kusui T, Pradhan TK, Battey JF, Jensen RT. (1995) Expression and characterization of cloned human bombesin receptors. *Mol Pharmacol.* 47:10-20.
3. Roesler R, Kapczinski F, Quevedo J, Dal Pizzol F, Schwartzmann G (2007) The gastrin-releasing peptide receptor as a therapeutic target in central nervous system disorders. *Recent Pat CNS Drug Discov.* 2:125-129.
4. Cornelio DB, Roesler R, Schwartzmann G (2007) Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. *Ann Oncol.* 18:1457-1466.
5. Jensen RT, Battey JF, Spindel ER, Benya RV (2008) International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states *Pharmacol Rev.* 60:1-42.
6. Gonzalez N, Moody TW, Igarashi H, Ito T, Jensen RT (2009) Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states *Curr Opin Endocrinol Diabetes Obes.* 15:58-64.
7. Li X, Lv Y, Yuan A, Yi S, Ma Y, Li Z. (2010) Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation. *Oncol Rep.* 24:441-448. *This publication suggests that the AlphaScreen® SureFire® ERK1/2 assay may be an alternative assay for the BB₂ receptor.*



Materials and Instrumentation

The following tables provide the references of compounds and reagents used or recommended for the characterization of the human Bombesin receptor BB₂ ValiScreen® cell line, as well as some advice on how to use these compounds:

Table 1. References of compounds used for functional characterization and binding assays

Name	Provider	Cat no	Working Stock Solution
Gastrin-Releasing Peptide (human) (GRP)	Bachem	H-6785	100 µM in PBS+0.1% protease-free BSA
Neuromedin B (NMB)	Sigma	N3762	500 µM in PBS+0.1% protease-free BSA
(D-Phe ⁶ , Leu-NHEt ¹³ , des-Met ¹⁴)-Bombesin (6-14)	Bachem	H-3042	1 mM in PBS+0.1% protease-free BSA
[¹²⁵ I]Gastrin Releasing Peptide ([¹²⁵ I]-GRP)	Revvity	NEX421	N/A

Table 2. References of cell culture media and assay buffers

Name	Provider	Cat no
HAM's F-12	Hyclone	SH30026.02
DMEM	Hyclone	SH30022.02
Advanced DMEM/F12 (serotonin receptors)	Invitrogen	12634-010
EMEM	BioWitthaker	06-174G
EX-CELL DHFR [®] media (DHFR deficient cell lines)	Sigma	C8862
FBS	Wisent	80150
FBS dialyzed	Wisent	80950
G418 (geneticin)	Wisent	400-130-IG
Zeocin	Invitrogen	R25005
Blasticidin	invitrogen	R210-01
Puromycin	Wisent	400-160-EM
Standard HBSS (with CaCl ₂ and MgCl ₂)	GIBCO	14025
HEPES	MP Biomedicals, LLC	101926
BSA, Protease-free	Sigma	A-3059
PEI	Sigma	P3143
Trypsin-EDTA	Hyclone	SH30236.02
Sodium Pyruvate	GIBCO	11360
L-Glutamine	GIBCO	25030
NEAA (non-essential amino acids)	GIBCO	11140
Forskolin	Sigma	F6886

This product is not for resale or distribution except by authorized distributors. The information provided in this document is valid for the specified lot number and date of analysis. This information is for reference purposes only and does not constitute a warranty or guarantee of the product's suitability for any specific use. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume any liability for any errors or damages arising from the use of this document or the product described herein. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF.



Revvity
940 Winter Street
Waltham, MA 02451 USA

(800) 762-4000
www.revvity.com

For a complete listing of our global offices, visit www.revvity.com
Copyright © 2023, Revvity, Inc. All rights reserved.